Trial reportCardiovascular ultrasound2016
Coronary flow velocity reserve by echocardiography: feasibility, reproducibility and agreement with PET in overweight and obese patients with stable and revascularized coronary artery disease.
Trial report in Cardiovascular ultrasound, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Coronary Microvascular Dysfunction in Patients with Congenital Heart Disease.Current cardiology reviews · 2023Pooled it
- Comprehensive treatment of microvascular angina in overweight women - a randomized controlled pilot trial.PloS one · 2020Trial
- Intra-Individual Variability of Myocardial Blood Flow and Flow Reserve Assessed by [Diagnostics (Basel, Switzerland) · 2026Article
- Duration of adenosine-induced myocardial hyperaemia: insights from quantitative 13N-ammonia positron emission tomography myocardial perfusion imaging.European heart journal. Cardiovascular Imaging · 2024Article
- Correlation of Non-Invasive Transthoracic Doppler Echocardiography with Invasive Doppler Wire-Derived Coronary Flow Reserve and Their Impact on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention.Journal of clinical medicine · 2024Article
- Noninvasive transthoracic doppler flow velocity and invasive thermodilution to assess coronary flow reserve.Quantitative imaging in medicine and surgery · 2024Article
- The Relationship between Coronary Flow Reserve and the TyG Index in Patients with Gestational Diabetes Mellitus.Medicina (Kaunas, Lithuania) · 2023Article
- Multimodality Cardiac Imaging in COVID.Circulation research · 2023Review
- Validation of pressure-bounded coronary flow reserve using invasive coronary physiologic assessment.Heart and vessels · 2023Article
- Current Concepts and Future Applications of Non-Invasive Functional and Anatomical Evaluation of Coronary Artery Disease.Life (Basel, Switzerland) · 2022Review
- Determination of [N-13]-ammonia extraction fraction in patients with coronary artery disease by calibration to invasive coronary and fractional flow reserve.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction.European journal of heart failure · 2022Article
- Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.Cardiac failure review · 2022Review
- The utility of cardiovascular imaging in heart failure with preserved ejection fraction: diagnosis, biological classification and risk stratification.Heart failure reviews · 2021Review
- Coronary microvascular dysfunction is associated with degree of anaemia in end-stage renal disease.BMC cardiovascular disorders · 2021Article
- Advances in translational imaging of the microcirculation.Microcirculation (New York, N.Y. : 1994) · 2021Review
- Doppler Echocardiography Assessment of Coronary Microvascular Function in Patients With Angina and No Obstructive Coronary Artery Disease.Frontiers in cardiovascular medicine · 2021Review
- Impaired coronary flow velocity reserve is associated with cardiovascular risk factors but not with angina symptoms.Open heart · 2021Article
- Outpatient Management of Patients With Angina With No Obstructive Coronary Arteries: How to Come to a Proper Diagnosis and Therapy.Frontiers in cardiovascular medicine · 2021Review
- Coronary flow velocity reserve and inflammatory markers in living kidney donors.International journal of cardiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary flow velocity reserve (CFVR) measured by transthoracic Doppler echocardiography of the LAD is used to assess microvascular function but validation studies in clinical settings are lacking. We aimed to assess feasibility, reproducibility and agreement with myocardial flow reserve (MFR) measured by PET in overweight and obese patients.
methodsParticipants with revascularized coronary artery disease were examined by CFVR. Subgroups were examined by repeated CFVR (reproducibility) or Rubidium-82-PET (agreement). To account for time variation, results were computed for scans performed within a week (1-week) and for all scans regardless of time gap (total) and to account for scar tissue for patients with and without previous myocardial infarction (MI).
resultsEighty-six patients with median BMI 30.9 (IQR 29.4-32.9) kg × m(-2) and CFVR 2.29 (1.90-2.63) were included. CFVR was feasible in 83 (97 %) using a contrast agent in 14 %. For reproducibility overall (n = 21) limits of agreement (LOA) were (-0.75;0.71), within-subjects coefficient of variation (CV) 11 %, and reliability 0.84. For reproducibility within 1-week (n = 13) LOA were (-0.33;0.25), within-subjects CV 5 %, and reliability 0.97. Agreement with MFR of the LAD territory (n = 35) was without significant bias and overall LOA were (-1.40;1.46). Agreement was best for examinations performed within 1-week of participants without MI of the LAD-territory (n = 12); LOA = (-0.68;0.88).
conclusionsCFVR was highly feasible with a good reproducibility on par with other contemporary measures applied in cardiology. Agreement with MFR was acceptable, though discrepancy related to prior MI has to be considered. CFVR of LAD is a valid tool in overweight and obese patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.